InVitae (NVTA) Tops Q4 EPS by 5c, Revenues Beat

InVitae (NYSE: NVTA) reported Q4 EPS of ($0.40), $0.05 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $45.36 million versus the consensus estimate of $40.78 million.

"In just five years, we have provided more than half a million people with high quality, comprehensive, affordable genetic information to inform healthcare decisions across all stages of life," said Sean George, co-founder and chief executive officer of Invitae. "We believe we're on an unprecedented growth trajectory that translates into better health decisions informed by genetic information. Our seemingly audacious mission to bring genetics into mainstream medicine and benefit people through all stages of life, is coming into clear focus - not only in diagnosing disease, but in helping people as they think about starting a family or informing those who want to be proactive about their health."

For earnings history and earnings-related data on InVitae (NVTA) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• CAE, Inc. (CAE) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY27 EPS Guidance
• Epsilon Energy Ltd. (EPSN) Reports Q2 EPS of $0.23